Back to top

dna-sequencing: Archive

Zacks Equity Research

REGN Signs $256M Buyout Deal With 23andMe to Boost Genomics Research

Regeneron is set to acquire 23andMe assets for $256 million to boost genetic drug discovery. The transaction is expected to close by third-quarter 2025.

REGNPositive Net Change BAYRYPositive Net Change HALOPositive Net Change ALLOPositive Net Change

Urmimala Biswas

Tap Billion-Dollar AI Opportunity in Oncology: Stocks in the Spotlight

Betting on AI-driven precision oncology companies presents a compelling long-term opportunity for investors. Some of the stocks in focus are BTAI, TEM and DGX.

DGXPositive Net Change NVDANegative Net Change BTAINegative Net Change PLTRNegative Net Change TEMNegative Net Change